Racial differences in management and outcomes of acute myocardial infarction during COVID-19 pandemic.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
05 2021
Historique:
received: 25 09 2020
revised: 27 12 2020
accepted: 30 12 2020
pubmed: 10 3 2021
medline: 20 4 2021
entrez: 9 3 2021
Statut: ppublish

Résumé

There are concerns that healthcare and outcomes of black, Asian and minority ethnic (BAME) communities are disproportionately impacted by the COVID-19 pandemic. We investigated admission rates, treatment and mortality of BAME with acute myocardial infarction (AMI) during COVID-19. Using multisource national healthcare records, patients hospitalised with AMI in England during 1 February-27 May 2020 were included in the COVID-19 group, whereas patients admitted during the same period in the previous three consecutive years were included in a pre-COVID-19 group. Multilevel hierarchical regression analyses were used to quantify the changes in-hospital and 7-day mortality in BAME compared with whites. Of 73 746 patients, higher proportions of BAME patients (16.7% vs 10.1%) were hospitalised with AMI during the COVID-19 period compared with pre-COVID-19. BAME patients admitted during the COVID-19 period were younger, male and likely to present with ST-elevation acute myocardial infarction. COVID-19 BAME group admitted with non-ST-elevation acute myocardial infarction less frequently received coronary angiography (86.1% vs 90.0%, p<0.001) and had a longer median delay to reperfusion (4.1 hours vs 3.7 hours, p<0.001) compared with whites. BAME had higher in-hospital (OR 1.68, 95% CI 1.27 to 2.28) and 7-day mortality (OR 1.81 95% CI 1.31 to 2.19) during COVID-19 compared with pre-COVID-19 period. In this multisource linked cohort study, compared with whites, BAME patients had proportionally higher hospitalisation rates with AMI, less frequently received guidelines indicated care and had higher early mortality during COVID-19 period compared with pre-COVID-19 period. There is a need to develop clinical pathways to achieve equity in the management of these vulnerable populations.

Identifiants

pubmed: 33685933
pii: heartjnl-2020-318356
doi: 10.1136/heartjnl-2020-318356
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

734-740

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Muhammad Rashid (M)

Keele Cardiovascular Research Group, School of Medicine, Keele University, Keele, UK.
Department of Cardiology, Royal Stoke University Hospital, Stoke On Trent, UK.

Adam Timmis (A)

NIHR Cardiovascular Biomedical Research Unit, Bart's Heart Centre, London, UK.

Tim Kinnaird (T)

Department of Cardiology, University Hospital of Wales, Cardiff, UK.

Nick Curzen (N)

Coronary Research Group, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Azfar Zaman (A)

Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, UK.

Ahmad Shoaib (A)

Keele Cardiovascular Research Group, School of Medicine, Keele University, Keele, UK.
Department of Cardiology, Royal Stoke University Hospital, Stoke On Trent, UK.

Mohamed O Mohamed (MO)

Keele Cardiovascular Research Group, School of Medicine, Keele University, Keele, UK.

Mark A de Belder (MA)

National Institute for Cardiovascular Outcomes Research, Bart's Health NHS Trust, London, UK.

John Deanfield (J)

Institute of Cardiovascular Sciences, University College London, London, UK.

Glen Philip Martin (GP)

Division of informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Jianhua Wu (J)

Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.

Chris P Gale (CP)

Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.
Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Mamas Mamas (M)

Keele Cardiovascular Research Group, School of Medicine, Keele University, Keele, UK mamasmamas1@yahoo.co.uk.
Department of Cardiology, Royal Stoke University Hospital, Stoke On Trent, UK.
Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH